combination of an epidermal growth factor receptor (EGFR) inhibitor and a vascular endothelial growth factor (VEGF) inhibitor. Case Presentation During a workup for chest pain in a 77-year-old Caucasian woman, a 3-cm liver lesion was found incidentally
Search Results
Amy Zhou, Manik Amin, Kathryn J. Fowler, Elizabeth M. Brunt, Jesse Keller, and Benjamin Tan
David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Thomas J. Dilling, M. Chris Dobelbower, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Lee M. Krug, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Steven E. Schild, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes
actionable genetic alterations: anaplastic lymphoma kinase ( ALK ) gene rearrangements and sensitizing epidermal growth factor receptor ( EGFR ) mutations. The complete version of the NCCN Guidelines addresses all aspects of management for NSCLC, including
Leora Horn
factor receptor ( EGFR ) and anaplastic lymphoma kinase ( ALK ) mutational testing is a category 1 recommendation. If the histology is squamous cell carcinoma, the NCCN Guidelines suggest that both EGFR and ALK mutational testing be considered
Robert A. Figlin, Elizabeth Brown, Andrew J. Armstrong, Wallace Akerley, Al B. Benson III, Harold J. Burstein, David S. Ettinger, Phillip G. Febbo, Matthew G. Fury, Gary R. Hudes, Merrill S. Kies, Eunice L. Kwak, Robert J. Morgan Jr., Joanne Mortimer, Karen Reckamp, Alan P. Venook, Frank Worden, and Yun Yen
combination with mTOR inhibitors in cancer therapy. Abbreviations: EGFR, epithelial growth factor receptor; HIF, hypoxia-inducible factors; MEK, mitogen-activated extracellular kinase; mTOR, mammalian target of rapamycin; PDGFR, platelet-derived growth factor
Presented by: Dara L. Aisner and Gregory J. Riely
found that the third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib improved 3-year disease-free survival in stage IB–III, EGFR -positive NSCLC. 4 “This study galvanized the push for earlier testing in NSCLC,” Dr. Aisner stated. The 2021
Presented by: Gregory J. Riely
classified according to mutations and gene fusions. The guidelines highlight some key molecular subtypes that should be included in molecular testing: EGFR sensitizing mutations, ALK gene rearrangements, ROS1 rearrangements, BRAF mutations, RET
Presented by: Dustin A. Deming
molecular features of the tumor. Across the continuum of treatment, patients usually received FOLFOX (5-FU/leucovorin/oxaliplatin) and/or FOLFIRI (5-FU/leucovorin/irinotecan) ± bevacizumab and an agent targeting the epidermal growth factor receptor (EGFR
Tatjana Gavrancic and Yeun-Hee Anna Park
the literature Examine the use of sorafenib in combination with platinum-based doublet chemotherapy in EGFR wild-type HAL H epatoid adenocarcinoma of the lung (HAL) is an extremely rare cancer that lacks treatment guidance and has a poor
Philip E. Lammers and Leora Horn
molecular mutation thought to drive tumor growth. 4 However, only patients with epidermal growth factor receptor (EGFR) mutations (approximately 10%-15%) or anaplastic lymphoma kinase (ALK) rearrangements (approximately 5%) have an FDA-approved therapy
Ryan D. Gentzler and Jyoti D. Patel
erlotinib and crizotinib for epidermal growth factor receptor ( EGFR )-mutated and anaplastic lymphoma kinase ( ALK )-rearranged NSCLC, respectively. This article focuses on the first-line treatment of NSCLC with no identifiable mutations with FDA
